JWCAR 201
Alternative Names: JWCAR-201Latest Information Update: 23 Sep 2024
At a glance
- Originator Shanghai Ming Ju Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Haematological malignancies
Most Recent Events
- 22 Aug 2024 Preclinical trials in Autoimmune disorders in China (Parenteral)
- 22 Aug 2024 Preclinical trials in Haematological malignancies in China (Parenteral)
- 22 Aug 2024 Shanghai Ming Ju Biotechnology plans phase-I trial for Haematological malignancies and Autoimmune disorders in China (Parenteral) in September 2024 (NCT06567080)